Guideline Updates G27: Beyond Beta-Blockers: The 2023 Chronic Coronary Disease Guideline

The 2023 AHA/ACC chronic coronary disease guideline renames stable ischemic heart disease, elevates SGLT2 inhibitors and GLP-1 therapies, de-escalates routine long-term beta-blockers, and ties revascularization to symptoms rather than ischemia alone